Drug Trial Radar · NCT06629779
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
900
Planned (sponsor's estimate)
Start
Oct 22, 2024
Primary completion
Sep 30, 2027
Study completion Nov 30, 2028
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Oct 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Conditions
- Metastatic Castration-Resistant Prostate Cancer
Interventions
PF-06821497Drug
Oral continuous
PlaceboDrug
Oral continuous
EnzalutamideDrug
Oral continuous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Radiographic Progression Free Survival (rPFS)Time frame: Randomization up to approximately 3 years
Locations
203 sites in 26 countries. Site status is shown where the registry gives one.
Ironwood Cancer & Research Centers
Chandler, Arizona
Ironwood Cancer & Research Centers
Gilbert, Arizona
Palo Verde Hematology Oncology
Glendale, Arizona
Ironwood Cancer & Research Centers
Glendale, Arizona
Ironwood Cancer & Research Centers
Goodyear, Arizona
Ironwood Cancer & Research Centers
Mesa, Arizona
Ironwood Cancer & Research Centers
Mesa, Arizona
Ironwood Cancer & Research Centers
Phoenix, Arizona
Ironwood Cancer & Research Centers
Scottsdale, Arizona
Highlands Oncology
Fayetteville, Arkansas
Highlands Oncology
Rogers, Arkansas
Highlands Oncology Group
Springdale, Arkansas
Los Angeles Cancer Network (LACN)
Anaheim, California
Los Angeles Cancer Network (LACN)
Fountain Valley, California
Los Angeles Cancer Network (LACN)
Glendale, California
Los Angeles Cancer Network (LACN)
Glendale, California
Los Angeles Cancer Network (LACN)
Laguna Hills, California
Los Angeles Cancer Network (LACN)
Los Angeles, California
Los Angeles Cancer Network (LACN)
Los Angeles, California
Blessing Hospital
Quincy, Illinois
Blessing Physician Services
Quincy, Illinois
Montefiore Medical Center - Medical Park
The Bronx, New York
Montefiore Medical Center
The Bronx, New York
Harborview Medical Center
Seattle, Washington
Fred Hutchinson Cancer Center
Seattle, Washington
University of Washington Medical Center - Montlake
Seattle, Washington
IMAXE
Buenos Aires, Argentina
Centro Medico Fleischer
Buenos Aires, Argentina
Hospital Privado Centro Médico de Córdoba
Córdoba, Argentina
Centro de Urología (CDU)
CABA, Buenos Aires, Argentina
Hospital Sirio Libanes
Capital Federal, Buenos Aires, Argentina
Imagenes Mdq
Mar del Plata, Buenos Aires, Argentina
Instituto de Investigaciones Clínicas Mar del Plata
Mar del Plata, Buenos Aires, Argentina
Centro Medico Privado CEMAIC
Capital, Córdoba Province, Argentina
Instituto do Cancer Arnaldo Vieira de Carvalho
São Paulo, Brazil
IBCC - Núcleo de Pesquisa e Ensino
São Paulo, Brazil
Crio - Centro Regional Integrado de Oncologia
Fortaleza, Ceará, Brazil
Instituto D'Or de Pesquisa e Ensino (IDOR) - Filial Salvador
Salvador, Estado de Bahia, Brazil
Clinica Amo - Rio Vermelho
Salvador, Estado de Bahia, Brazil
Clinica Amo - Rio Vermelho
Salvador, Estado de Bahia, Brazil
Showing 40 of 203 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.